Gastrointestinal bleeding and endoscopic findings in critically and non-critically ill patients with corona virus disease 2019 (COVID-19): Results from Lean European Open Survey on SARS-CoV-2 (LEOSS) and COKA registries.
Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants
/ adverse effects
COVID-19
/ epidemiology
Child
Child, Preschool
Comorbidity
Critical Illness
Diverticular Diseases
/ diagnosis
Endoscopy, Gastrointestinal
Europe
/ epidemiology
Female
Gastroesophageal Reflux
/ complications
Gastrointestinal Hemorrhage
/ epidemiology
Hospitalization
Humans
Infant
Intensive Care Units
Male
Middle Aged
Peptic Ulcer
/ diagnosis
Registries
Severity of Illness Index
Young Adult
COVID-19
GI bleeding
LEOSS
SARS-CoV-2
critically ill
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
02
07
2021
accepted:
23
08
2021
pubmed:
17
10
2021
medline:
1
12
2021
entrez:
16
10
2021
Statut:
ppublish
Résumé
Corona virus disease 2019 (COVID-19) patients are at increased risk for thromboembolic events. It is unclear whether the risk for gastrointestinal (GI) bleeding is also increased. We considered 4128 COVID-19 patients enrolled in the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. The association between occurrence of GI bleeding and comorbidities as well as medication were examined. In addition, 1216 patients from COKA registry were analyzed focusing on endoscopy diagnostic findings. A cumulative number of 97 patients (1.8%) with GI bleeding were identified in the LEOSS registry and COKA registry. Of 4128 patients from the LEOSS registry, 66 patients (1.6%) had a GI bleeding. The rate of GI bleeding in patients with intensive care unit (ICU) admission was 4.5%. The use of therapeutic dose of anticoagulants showed a significant association with the increased incidence of bleeding in the critical phase of disease. The Charlson comorbidity index and the COVID-19 severity index were significantly higher in the group of patients with GI bleeding than in the group of patients without GI bleeding (5.83 (SD = 2.93) vs. 3.66 (SD = 3.06), p < 0.01 and 3.26 (SD = 1.69) vs. 2.33 (SD = 1.53), p < 0.01, respectively). In the COKA registry 31 patients (2.5%) developed a GI bleeding. Of these, the source of bleeding was identified in upper GI tract in 21 patients (67.7%) with ulcer as the most frequent bleeding source (25.8%, n = 8) followed by gastroesophageal reflux (16.1%, n = 5). In three patients (9.7%) GI bleeding source was located in lower GI tract caused mainly by diverticular bleeding (6.5%, n = 2). In seven patients (22.6%) the bleeding localization remained unknown. Consistent with previous research, comorbidities and disease severity correlate with the incidence of GI bleeding. Also, therapeutic anticoagulation seems to be associated with a higher risk of GI bleeding. Overall, the risk of GI bleeding seems not to be increased in COVID-19 patients.
Sections du résumé
BACKGROUND
Corona virus disease 2019 (COVID-19) patients are at increased risk for thromboembolic events. It is unclear whether the risk for gastrointestinal (GI) bleeding is also increased.
METHODS
We considered 4128 COVID-19 patients enrolled in the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. The association between occurrence of GI bleeding and comorbidities as well as medication were examined. In addition, 1216 patients from COKA registry were analyzed focusing on endoscopy diagnostic findings.
RESULTS
A cumulative number of 97 patients (1.8%) with GI bleeding were identified in the LEOSS registry and COKA registry. Of 4128 patients from the LEOSS registry, 66 patients (1.6%) had a GI bleeding. The rate of GI bleeding in patients with intensive care unit (ICU) admission was 4.5%. The use of therapeutic dose of anticoagulants showed a significant association with the increased incidence of bleeding in the critical phase of disease. The Charlson comorbidity index and the COVID-19 severity index were significantly higher in the group of patients with GI bleeding than in the group of patients without GI bleeding (5.83 (SD = 2.93) vs. 3.66 (SD = 3.06), p < 0.01 and 3.26 (SD = 1.69) vs. 2.33 (SD = 1.53), p < 0.01, respectively). In the COKA registry 31 patients (2.5%) developed a GI bleeding. Of these, the source of bleeding was identified in upper GI tract in 21 patients (67.7%) with ulcer as the most frequent bleeding source (25.8%, n = 8) followed by gastroesophageal reflux (16.1%, n = 5). In three patients (9.7%) GI bleeding source was located in lower GI tract caused mainly by diverticular bleeding (6.5%, n = 2). In seven patients (22.6%) the bleeding localization remained unknown.
CONCLUSION
Consistent with previous research, comorbidities and disease severity correlate with the incidence of GI bleeding. Also, therapeutic anticoagulation seems to be associated with a higher risk of GI bleeding. Overall, the risk of GI bleeding seems not to be increased in COVID-19 patients.
Identifiants
pubmed: 34655180
doi: 10.1002/ueg2.12165
pmc: PMC8598966
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1090Subventions
Organisme : Deutsches Zentrum für Infektionsforschung
Organisme : Willy Robert Pitzer Foundation
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Blood Adv. 2018 Nov 27;2(22):3198-3225
pubmed: 30482763
Dtsch Arztebl Int. 2021 Jan 11;118(Forthcoming):
pubmed: 33531113
J Intern Med. 2021 Jun;289(6):887-894
pubmed: 33341978
Z Gastroenterol. 2017 Sep;55(9):883-936
pubmed: 29186643
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2103-2109
pubmed: 33161221
Am J Gastroenterol. 2020 Jul 1;115(7):1139-1140
pubmed: 32618672
N Engl J Med. 2018 Jun 28;378(26):2506-2516
pubmed: 29949497
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
United European Gastroenterol J. 2021 Nov;9(9):1081-1090
pubmed: 34655180
Sci Rep. 2020 Oct 7;10(1):16726
pubmed: 33028914
N Engl J Med. 2020 Oct 8;383(15):1483-1488
pubmed: 32706956
Drug Saf. 2004;27(6):411-20
pubmed: 15144234
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
BMC Gastroenterol. 2020 Sep 29;20(1):318
pubmed: 32993509
Dig Liver Dis. 2015 Aug;47(8):621-7
pubmed: 25935464
J Hosp Med. 2006 Jan;1(1):13-20
pubmed: 17219466
Clin Imaging. 2021 May;73:86-95
pubmed: 33341452
Sci Data. 2020 Dec 10;7(1):435
pubmed: 33303746
Gastrointest Endosc. 2020 Jul;92(1):192-197
pubmed: 32179106
Gut. 2021 Apr;70(4):717-724
pubmed: 32747412
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1735-1743
pubmed: 27515592
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345
Gastroenterol Rep (Oxf). 2020 Dec 10;9(1):85-87
pubmed: 33747531
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569